Moffett Brady S, Allen Joseph, Khichi Mahmood, McCann-Crosby Bonnie
J Pediatr Pharmacol Ther. 2021;26(2):194-199. doi: 10.5863/1551-6776-26.2.194. Epub 2021 Feb 15.
To determine whether obese and overweight pediatric patients with new onset diabetic ketoacidosis (DKA) treated with continuous infusion insulin have increased time to subcutaneous insulin initiation or adverse events as compared with patients with normal body habitus.
A retrospective, cohort study was designed that included patients 2 to 18 years of age admitted with new onset DKA who received continuous infusion insulin from January 1, 2011, to December 31, 2017. Patients were stratified according to BMI percentile with the primary outcome of time to initiation of subcutaneous insulin. Secondary endpoints included time to minimum beta-hydroxybutyrate, and incidence of hypoglycemia or other adverse events.
A total of 337 patients (46.6% male, 9.6 ± 3.8 years of age) met study criteria. Patients were classified by body habitus as obese (7.7%, n = 26), overweight (7.1%, n = 24), normal body weight (58.8%, n = 198), or underweight (26.4%, n = 89), based on BMI percentile. Most patients were initiated on insulin at 0.1 unit/kg/hr (86.7%) for 16.7 ± 7.0 hours. Time from continuous infusion insulin initiation to subcutaneous insulin was not different between body habitus groups, nor was hypoglycemia or the use of mannitol (p > 0.05). Median time to lowest beta-hydroxybutyrate was greater for obese (26.4, IQR [13.9, 41.9]) and overweight (32.4, IQR [18.3, 47.0]) groups than for normal body habitus patients (16.5, IQR [12.3, 23.8]) (p < 0.05).
Time to subcutaneous insulin and adverse events was not associated with body habitus, but obese and overweight patients may have delayed beta-hydroxybutyrate clearance.
确定与体型正常的患者相比,接受持续静脉输注胰岛素治疗的新发糖尿病酮症酸中毒(DKA)的肥胖和超重儿科患者开始皮下注射胰岛素的时间是否延长或不良事件是否增加。
设计了一项回顾性队列研究,纳入2011年1月1日至2017年12月31日期间因新发DKA入院并接受持续静脉输注胰岛素治疗的2至18岁患者。根据BMI百分位数对患者进行分层,主要结局为开始皮下注射胰岛素的时间。次要终点包括达到最低β-羟基丁酸的时间以及低血糖或其他不良事件的发生率。
共有337例患者(46.6%为男性,年龄9.6±3.8岁)符合研究标准。根据BMI百分位数,患者按体型分为肥胖(7.7%,n=26)、超重(7.1%,n=24)、正常体重(58.8%,n=198)或体重过轻(26.4%,n=89)。大多数患者以0.1单位/千克/小时(86.7%)的剂量开始输注胰岛素,持续16.7±7.0小时。不同体型组从开始持续静脉输注胰岛素到开始皮下注射胰岛素的时间、低血糖发生率或甘露醇使用情况均无差异(p>0.05)。肥胖组(26.4,IQR[13.9,41.9])和超重组(32.4,IQR[18.3,47.0])达到最低β-羟基丁酸的中位时间长于体型正常的患者(16.5,IQR[12.3,23.8])(p<0.05)。
开始皮下注射胰岛素的时间和不良事件与体型无关,但肥胖和超重患者的β-羟基丁酸清除可能延迟。